详情页

当前位置：首页 > 详情页

Cisplatin potentiates PD-L1 expression more robustly than pemetrexed in malignant pleural mesothelioma: Temporal dynamics revealed by cellular and xenograft analyses

35| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Medical Imaging, The First Affiliated Hospital of Kunming Medical University, Kunming, China. [2]Pathology Department,The First Affiliated Hospital of Kunming Medical University, Kunming, China. [3]Department of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, China.

出处：

DOI：

ISSN：

关键词： Malignant pleural mesothelioma (MPM) Programmed death ligand 1 (PD-L1) Chemotherapy Immunotherapy Immune checkpoint inhibitors (ICIs)

摘要：

Chemotherapy may modulate PD-L1 expression in malignant pleural mesothelioma (MPM), influencing immune checkpoint inhibitor (ICI) efficacy. We compared cisplatin (CDDP) and pemetrexed (PEM) on PD-L1 dynamics in MPM.H226 (epithelial) and MSTO-211H (biphasic) cells were treated with CDDP/PEM for 12-48 h, with apoptosis analyzed by flow cytometry and PD-L1 by Western blot. Xenograft models (CDDP/PEM-treated mice) assessed tumor growth and PD-L1 via immunohistochemistry.Both drugs inhibited cell growth and induced apoptosis (CDDP > PEM, P < 0.05). Baseline PD-L1 was higher in MSTO-211H vs. H226 (P < 0.05). Chemotherapy upregulated PD-L1, peaking at 48 h (CDDP > PEM, P < 0.05). In xenografts, MSTO-211H tumors showed faster growth and higher PD-L1 (P < 0.05), further amplified by CDDP during progression.CDDP robustly potentiates PD-L1 in MPM, especially in biphasic subtypes. Temporal PD-L1 dynamics suggest chemotherapy-ICI synergy may depend on drug selection and treatment timing.Copyright © 2025. Published by Elsevier GmbH.

基金：

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2026]版：

无

最新[2025]版：

大类 | 4 区医学

小类 | 3 区病理学

JCR分区：

出版当年[2025]版：

无

最新[2024]版：

Q2 PATHOLOGY

影响因子： 3.2 最新[2024版] 2.8 最新五年平均 0 出版当年[2025版] 0 出版当年五年平均 3.2 出版前一年[2024版]

第一作者：

第一作者机构： [1]Department of Medical Imaging, The First Affiliated Hospital of Kunming Medical University, Kunming, China.

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Detection of PD-L1 expression levels in malignant pleural mesothelioma with a targeted MRI nanoprobe in vivo [2]The prospect of immunotherapy combined with chemotherapy in patients with advanced non-small cell lung cancer: a narrative review [3]Chemotherapy combined with immunotherapy in a patient with multiple primary gastric and rectal cancers with good prognosis: A case report [4]支气管动脉灌注化疗加免疫治疗肺癌伴恶性胸水的临床研究 [5]DCs-CIK细胞免疫治疗联合化疗治疗晚期非小细胞肺癌的疗效观察 [6]支气管动脉灌注化疗加免疫治疗肺癌伴恶性胸水的临床研究 [7]Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis (PARECEC) [8]脓毒症免疫抑制机制及免疫治疗的研究进展 [9]New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma [10]Neoantigen immunotherapy: a novel treatment for bladder cancer